Bioequivalence and Bioavailability Forum

Hi all,

❝ I would like to know in this situation which one you will select between including group effect and single analysis, because I would like to include group effect in the model. Neither, I haven't seen a single study in Thailand where a group effect was included in the model. So the way to do the study smoothly I ready to do, time wasting to argue with Thai FDA.

Not exactly sure I know the meaning of the question, but I am sure I need to improve my understanding of the need for the group effect when groups are separated.
What do we test for specifically, and what do we conclude if the resulting p-value is low?

I have not read any papers on this issue. I would think that group is a between-factor, so the anova residual will not depend on whether or not group is added as a factor in the lm. In fact I would also be inclined to think that group*treatment would be a potentially relevant test. What would you experts think of group or group*treatment coming out significant? Nothing? Something?
We could in theory get LSMeans for Treatment T and R in both groups, and if group*treatment is significant it implies that T/R may differ between the two groups (which could suggest they may differ in time). This is a cosmic mindf&#ker to me. You experts out there got a qualified view on this?

Many thanks and best regards,
EM.